AbbVie (ABBV)

Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.8% year on year to $13.98 billion. Its non-G...

Sonoco Products Company delivers packaging solutions to global consumer and industrial markets, with a reported dividend yield of 4.2%.

What Happened? Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.5% in the afternoon session after the company reported first-quarter results that...

AbbVie (ABBV) Q1 2026 Earnings Transcript

Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q1 CY2026, with sales up 12.4% year on year to $15 billion. Its non-GAAP ...

Mind your investment horizon.

Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Wednesday before market hours. Here’s what to expect. AbbVie beat analysts...

This pharma stock is cheap for a reason.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stoc...

Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

These stocks pay juicy dividends but also offer much more.

These stocks are keepers.

Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and Reclaiming Your Life.

The pharma giant is still a rock-solid dividend stock.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

These stocks pay between 3.3% and 6.3% and are backed by strong financials.

AbbVie is making progress in this market, but it is still far behind the leader.

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc. (Nasdaq: RVMD) released topline Phase 3 results from its RASolute 302 trial, effectively setting a new standard of care in the treatment of pancreatic cancer. For [...]

The U.S. economy could be starting a vicious cycle if this indicator is right.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an industry often characterized by volatile "one-hit wonders" and aggressive M&A cycles, Regeneron has carved out a unique identity as a founder-led, R&D-centric powerhouse. Currently, [...]

There are still some generous yielders if you know where to look.